BioDelivery Sciences signs deal with nonprofit group

01/26/2009 | Pharmaceutical Business Review Online

BioDelivery Sciences International has agreed to work with the nonprofit Drugs for Neglected Diseases initiative in testing the safety and efficacy of Bioral Amphotericin B, a treatment for leishmaniasis, Chagas' disease and other communicable diseases. Bioral Amphotericin B uses BDSI's patented Bioral drug delivery technology to allow the drug to be administered orally rather than intravenously.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Director of Operations - GBS
Mayo Clinic
Rochester, MN